智通财经APP获悉，日前，映恩生物(Duality Biologics)宣布与GSK(GSK.US)已就一项抗体偶联药物(ADC)DB-1324达成独家授权协议。根据协议，GSK将获得该ADC药物的全球(不包括中国大陆、香港地区和澳门地区)独家授权，以推进该疗法的研发与商业化进程。
根据协议条款，GSK将预先支付3000万美元预付款及其他行权前里程碑付款以获得在全球范围内(中国大陆、香港地区和澳门地区除外)推进DB-1324研发和商业化的独家授权许可。如果GSK行使许可权，映恩生物将收取行权费以及后续在开发、法规注册和商业化不同阶段的里程碑付款，最高可达9.75亿美元。
DB-1324是一种创新ADC分子，基于映恩生物独有且经过临床验证过的Duality Immune Toxin Antibody Conjugates(DITAC)平台开发而成。目前还处于临床前开发阶段，其研究方向可能针对胃肠道(GI)癌症。此外，该ADC药物有潜力与GSK多个抗肿瘤产品联合用药，从而战略性地补充GSK的肿瘤产品组合。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.